The role of FDG PET in the clinical management of head and neck cancer

Oral Oncology

Volumn 34, Issue 6, 1998, Pages 466-471

  Stokkel, M P M ^a   Ten Broek, F W ^a   Van Rijk, P P ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

FDG; Head and neck cancer; PET

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

CANCER DIAGNOSIS; DIAGNOSTIC IMAGING; HEAD AND NECK CANCER; HUMAN; LYMPH NODE METASTASIS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; SQUAMOUS CELL CARCINOMA;

EID: 0031760945     PISSN: 13688375     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1368-8375(98)00050-5     Document Type: Article

References (63)

1. Warburg, O. The Metabolism of Tumors. New York: Smith RR, 1931, 129-69.
2. Warburg O. On the origin of cancer cells. Science. 123:1956;309-314.
3. Hartung T., Buchler M., Grimmel S., Kornrumpf D., Beger H. G., Reske S. N. Correlation increased FDG-uptake and elevated expression of glucose transporter 1 gene in human pancreatic carcinoma. European Journal of Nuclear Medicine. 21:S17:1994.
4. Yamamoto T., Seino Y., Fukumoto H., et al. Overexpression of facilitated glucose transporter genes in human cancer. Biochem Biophys Res Commun. 170:1990;223-230.
5. Nishioka T., Oda Y., Seino Y., et al. Distribution of the glucose transporters in human brain tumors. Cancer Research. 52:1992;3972-3979.
6. Gallagher B. M., Fowler J. S., Gutterson N. I., MacGregor R. R., Wan C. N., Wolf A. P. Metabolic trapping as a principle factor of radiopharmaceutical design: some factors responsible for the biodistribution of F-18-2-deoxy-2-fluoro-D-glucose. Journal of Nuclear Medicine. 19:1978;1154-1161.
7. Sokoloff L., Reivich M., Kennedy C., et al. The (C14)-deoxyglucose method for the measurement of local cerebral glucose utilization: theory, procedure and normal values on the conscious and anesthetized albino rat. Journal of Neurochemistry. 28:1977;897-916.
8. Minn H., Lekinen-Kallio S., Lindholm P., et al. F18-fluorodeoxyglucoce uptake in tumors: kinetic vs steady-state methods with reference to plasma insulin. Journal of Computer Assisted Tomography. 17:1993;115-123.
9. Wahl R. L., Clavo A. C. Effects of hypoxia on cultured human tumor cell uptake of thymidine, L-methionine and FDG. Journal of Nuclear Medicine. 34:1993;73P.
10. Wahl R. L., Kaminsky M. S., Ethier S. P., Hutchins G. D. The potential of 2-deoxy-2[F18]fluoro-D-glucose (FDG) for the detection of tumor involvement in lymph nodes. Journal of Nuclear Medicine. 31:1990;1831-1835.
11. Minn H., Joensuu H., Ahonen A., Klemi P. Fluorodeoxyglucose imaging: a method to assess the proliferative activity of human cancer in vivo. Cancer. 61:1988;1776-1781.
12. Haberkorn U., Strauss L. G., Reisser Ch, et al. Glucose uptakev perfusioncell proliferation in headneck tumors: relation of positron emission tomography to flow cytometry. Journal of Nuclear Medicine. 32:1991;1548-1555.
13. Steinkamp H. J., Maurer J., Heim T., Knoebber D., Felix R. Magnetresonanztomographie und computertomograpie im tumorstaging des mundhoehlen-/oropharynxkarzinoms. Hals-Nasen-Ohre Heilkunde, Kopf-und-hals-chirurgie. 41:1993;519-525.
14. Minn H., Lapela M., Klemi P. J., et al. Prediction of survival with fluorine-18-fluorodeoxyglucose and PET in head and neck cancer. Journal of Nucl Medicine. 38:1997;1907-1911.
15. McGuirt W. F., Keyes J. W., Greven K. M., et al. Preoperative identification of benign versus malignant parotid masses: a comparative study including positron emission tomography. Laryngoscope. 105:1995;579-584.
16. Keyes J. W. SUV: standard uptake or silly useless value. Journal of Nuclear Medicine. 36:1995;1836-1839.
17. Laubenbacher C., Saumweber D., Wagner-Manslau C., et al. Comparison of Fluorine-18 fluorodeoxyglucose PET, MRI and endoscopy for staging head and neck squamous-cell carcinomas. Journal of Nuclear Medicine. 36:1995;1747-1757.
18. Hamberg L. M., Hunter G. J., Alpert N. M., Choi N. C., Babich J. W., Fischman A. J. The dose uptake ratio as an index of glucose metabolism: useful parameter or oversimplification? Journal of Nuclear Medicine. 35:1994;1308-1312.
19. Zasadny K. R., Wahl R. L. Standardized uptake values of normal tissues at PET with 2-[fluorine-18]-fluoro-2-deoxy-D-glucose: variations with body weight and a method for correction. Radiology. 189:1993;847-850.
20. Langen K. J., Braun U., Kops E. R., et al. The influence of plasma glucose levels on Fluorine-18-fluorodeoxyglucose uptake in bronchial carcinomas. Journal of Nuclear Medicine. 34:1993;355-359.
21. Greco, FA, Hainsworth, JD. Cancer of unknown primary site. In: DeVita VT, Hellman S, Rosenberg SA, editors. Cancer: Principles and Practice of Oncology, 4th Edition. Philadelphia: JB Lippencott, 1993, p. 2072-92.
22. Mukherji S. K., Drane W. E., Mancuso A. A., Parsons J. T., Mendenhall W. M., Stringer S. Occult primary tumors of the head and neck: detection with 2-[F-18]fluoro-2-deoxy-D-glucose SPECT. Radiology. 199:1996;761-766.
23. Braams J. W., Pruim J., Kole A. C., et al. Detection of unknown primary head and neck tumors by positron emission tomography. International Journal of Oral Maxillofacial Surgery. 26:1997;112-115.
24. Snow G. B., Patel P., Leemans C. R., Tiwari R. Management of cervical lymph nodes in patients with head and neck cancer. European Archives of Otolaryngology. 249:1992;187-194.
25. Lindberg R. Distribution of cervical lymph node metastasis from squamous cell carcinoma of the upper respiratory and digestive tracts. Cancer. 29:1972;1446-1449.
26. Snow G. B., Annyas A. A., van Slooten E. A., Bartelink G. G. M., Hart A. A. M. Prognostic factors of neck node metastases. Clinical Otolaryngology. 7:1982;185-192.
27. Cachin Y., Sancho-Garnier H., Micheau C., Marandas P. Nodal metastasis from carcinoma of the oropharynx. Otolaryngologic Clinics of North America. 12:1979;145-154.
28. Ali S., Tiwari R. M., Snow G. B. False positive and false negative neck nodes. Head and Neck. 8:1985;78-82.
29. Byers R. M., Wolf P. F., Ballantyne A. J. Rationale for elective modified neck dissection. Head and Neck. 10:1988;160-167.
30. Jesse R. H., Barkley H. T., Lindberg R. D., Fletcher G. H. Cancer of the oral cavity: is elective neck dissection beneficial? American Journal of Surgery. 120:1970;505.
31. Friedman M., Mafee M. F., Pacella B. L., Strorigl T. L., Dew L. L., Toriumi D. M. Rationale for elective neck dissection in 1990. Laryngoscope. 100:1990;54-59.
32. Hillsamer P. J., Schuller D. E., McGhee R. B., Chakeres D., Young D. C. Improving diagnostic accuracy of cervical metastases with computed tomography and magnetic resonance imaging. Archives of Otolaryngology, Head and Neck Surgery. 116:1990;1297-1301.
33. van den Brekel M. W. M., Stel H. V., Castelijns J. A., et al. Cervical lymph node metastasis: assessment of radiologic criteria. Radiology. 177:1990;379-384.
34. Dillon W. P., Harnsberger H. R. The impact of radiologic imaging on staging of cancer of the head and neck. Seminars in Oncology. 18:1991;64-79.
35. Quetz Ju Rohr, Hoffman S., Wustrow P., Mertens J. B-image sonography in lymph node staging of the head and neck area. A comparison with palpation and computerized magnetic resonance tomography. Hals-Nasen-Ohre Heilkunde, Kopf-und-hals-chirurgie. 39:1991;61-63.
36. Van den Brekel M. W. M., Catelijns J. A., Croll G. A., et al. Magnetic resonance imaging versus palpation of cervical lymph node metastases. Archives of Otolaryngology, Head and Neck Surgery. 117:1991;666-673.
37. Van den Brekel M. W. M., Castelijns J. A., Stel H. V., et al. Occult metastatic neck disease: detection with ultrasound and ultra-sound guided fine needle aspiration cytology. Radiology. 178:1991;457-461.
38. Baillet J. W., Abemayor E., Jabour B. A., Hawkins R. A., Ho C., Ward P. H. Postitron emission tomography: a new, precise imaging modality for detection of primary head and neck tumors and assessment of cervical adenopathy. Laryngoscope. 102:1992;281-288.
39. Jabour B. A., Choi Y., Hoh C. K., et al. Extracranial head and neck: PET imaging with 2-[F-18]fluoro-2-deoxy-D-glucose and MR imaging correlation. Radiology. 186:1993;27-35.
40. McGuirt W. F., Greven K. M., Keyes J. W., et al. Positron emission tomography in the evaluation of laryngeal carcinoma. Annals of Otology, Rhinolgy and Laryngology. 104:1995;274-278.
41. Braams J. W., Pruim J., Freling N. J. M., et al. Detection of lymph node metastases of squamous-cell cancer of the head and neck with FDG-PET and MRI. Journal of Nuclear Medicine. 36:1995;211-216.
42. McGuirt W. F., Williams D. W., Keyes J. W., et al. A comparative diagnostic study of head and neck nodal metastases using positron emission tomography. Laryngoscope. 105:1995;373-375.
43. Abdel-Nabi H., Spaulding M. B., Behar P., Nguyen A., Simpson G., Gona J. Value of PET-FDG imaging in the pre-operative work-up of patients with head and neck carcinomas. Journal of Nuclear Medicine. 37:1996;136P.
44. Manolidis S., Isaacs R. S., Valk P. E., Pounds T. R., Abella-Columna E., Donald P. J. Staging head and neck cancer by whole-body PET-FDG imaging. Journal of Nuclear Medicine. 37:1996;136P.
45. Benchaou M., Lehman W., Slosman D. O., et al. The role of FDG-PET in the preoperative assessment of N-staging in head and neck cancer. Acta Otolaryngologia. 116:1996;332-335.
46. Bender H., Straehler-Pohl H. J., Schomburg A., et al. Value of F-18-DG-PET in the assessment of head and neck tumors. Journal of Nuclear Medicine. 38:1997;153P.
47. Eichhorn T., Schroeder H. G., Glanz H., et al. Histologisch kontrollierter vergleich von palpation and sonography bei der diagnose von halslymphknotenmetastasen. Laryngology, Rhinology and Otology. 66:1987;266-274.
48. Engenhart R., Kimmig B., Hover K. H., Strauss L. G., Lorenz W. J., Wannenmacher M. Photon-neutron therapy for recurrent colorectal cancer - follow up and preliminary results. Strahlentherapie und Onkologie. 166:1990;95-98.
49. Chaiken L., Rege S., Hoh C., et al. Positron emission tomography with fluorodeoxyglucose to evaluate tumor response and control after radiation therapy. International Journal of Radiation Oncology-Biology-Physics. 27:1993;455-464.
50. Greven K. M., Williams D. W., Keyes J. W., et al. Positron emission tomography of patients with head and neck carcinoma before and after high dose irradiation. Cancer. 74:1994;1355-1359.
51. Minn H., Paul R., Ahonen A. Evaluation of treatment response to radiotherapy in head and neck cancer with fluorine-18 fluorodeoxyglucose. Journal of Nucl Medicine. 29:1988;1521-1525.
52. Rege S. D., Chaiken L., Hoh C.K., et al. Change induced by radiation therapy in FDG uptake in normal and malignant structures of the head and neck: quantitation with PET. Radiology. 189:1993;807-812.
53. Lowe V. J., Dunphy F. R., Varvares M., et al. Evaluation of chemotherapy response in patients with advanced head and neck cancer using [F-18] fluorodeoxyglucose positron emission tomography. Head and Neck. 19:1997;666-674.
54. Haberkorn U., Strauss L. G., Dimitrakopoulou A., et al. Fluorodeoxyglucose imaging of advanced head and neck cancer after chemotherapy. Journal of Nucl Medicine. 34:1993;12-17.
55. Lapela M., Grenman R., Kurki T., et al. Head neck cancer: detection of recurrence with PET 2-[F-18]fluoro-2-deoxy-D-glucose. Radiology. 197:1995;205-211.
56. Anzai Y., Carroll W. R., Quint D. J., et al. Recurrence of head and neck cancer after surgery or irradiation: Prospective comparison of 2-deoxy-2[F-18] fluoro-D-glucose PET and MT imaging diagnosis. Radiology. 200:1996;135-141.
57. Strauss L. G. Fluorine-18 deoxyglucose and false positive results: a major problem in the diagnostic of oncological patients. European Journal of Nuclear Medicine. 23:1996;1409-1415.
58. Rigo P., Paulus P., Kaschten B. J., et al. Oncological applications of positron emission tomography with fluorine-18 fluorodeoxyglucose. European Journal of Nucl Medicine. 23:1996;1641-1674.
59. Engel H., Steinert H., Buck A., Berthold T., Huch Boni R. A., von Schulthess G. K. Whole-body PET: Physiological and artifactual fluorodeoxyglucose accumulations. Journal of Nuclear Medicine. 37:1996;441-446.
60. Lindholm P., Minn H., Leskinen-Kallio S., Bergman J. Influence ofthe blood glucose concentration on FDG uptake in cancer. A PET study. Journal of Nuclear Medicine. 13:1993;1-6.
61. van Lingen A., Huijgens P. C., Visser F. C., et al. Performance characteristics of a 511-KeV collimator for imaging positron emitters with a standard gamma-camera. European Journal of Nuclear Medicine. 19:1992;315-321.
62. Martin W. H., Delbeke D., Patton J. A., et al. FDG-SPECT: correlation with FDG-PET. Journal of Nucl Medicine. 36:1995;988-995.
63. Jarritt P. H., Acton P. D. PET imaging using gamma camera systems: a review. Nuclear Medicine Communications. 17:1996;758-766.